Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. filing amendment states that the reporting person, Jorey Chernett, no longer beneficially owns any shares of the company's common stock as of the close of business on May 19, 2026.
This Amendment No. 1 is an exit filing reflecting zero shares beneficially owned and reports 0% ownership of the class.
CalciMedica reported a profitable first quarter of 2026 and highlighted progress across its pipeline. Net income was $5.0 million for the quarter ended March 31, 2026, or $0.31 per basic share and $0.30 per diluted share, compared with a $5.0 million net loss a year earlier. Other income rose to $10.6 million, mainly from fair value adjustments to a promissory note and common stock warrants, while research and development and general and administrative expenses both declined year over year.
Cash and cash equivalents were $8.2 million as of March 31, 2026, and the company expects this to fund its current operating plan into the fourth quarter of 2026. CalciMedica expects FDA feedback in the second quarter of 2026 on the design of a potential pivotal Auxora program in acute pancreatitis and on potential future development in acute kidney injury, and it is advancing its oral CRAC inhibitor CM5480 toward an anticipated IND submission in pulmonary hypertension in 2027.
Soleus Private Equity group reports shared beneficial ownership of presently exercisable warrants to purchase 391,952 shares of CalciMedica, Inc. common stock. The filings show 195,976 warrants held by Soleus Private Equity Fund III and by Soleus Capital Master Fund, producing entity-level totals of 391,952 shares and a reported 2.4% ownership figure for certain Soleus entities. The percentage calculations use 15,743,916 shares outstanding as of February 25, 2026 per the Issuer's cited Form 10-K. Filers disclaim direct beneficial ownership other than for Section 13(d) purposes and attribute holdings to affiliated funds and managers.
CalciMedica, Inc. filed an amendment to its annual report to add detailed Part III disclosures on directors, executive officers, compensation, ownership and related-party transactions. The Board has seven members, a majority of whom are independent under Nasdaq rules, with key committees fully composed of independent directors.
The filing outlines 2025 pay for three named executives, including total compensation of $895,410 for CEO A. Rachel Leheny, $763,315 for Chief Medical Officer Sudarshan Hebbar and $703,558 for Chief Business Officer Eric Roberts, largely driven by stock option awards. It also lists extensive outstanding equity awards and change-in-control severance protections.
As of June 30, 2025, non-affiliates held common stock with an aggregate market value of about $15.7 million, and 15,743,916 shares were outstanding as of February 25, 2026. The amendment details equity plan capacity, a three-year clawback policy tied to restatements, related-party consulting and financing arrangements, and a $20.4 million 2024 private placement, including participation by major holders and insiders.
CalciMedica, Inc. Chief Financial Officer Stephen Bardin received a grant of employee stock options covering 67,728 shares of common stock at an exercise price of $0.585 per share. Beginning April 1, 2026, 1/48th of the option shares vest in equal monthly installments over four years, with vesting starting only after the company files a Form S-8 for shares added under its 2023 Equity Incentive Plan.
CalciMedica, Inc. reported that Chief Medical Officer Sudarshan Hebbar received an employee stock option grant covering 91,173 shares of common stock with an exercise price of $0.585 per share. All 91,173 options are held directly after this grant.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years, and no shares vest until the company files a Form S-8 covering shares added under its 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Business Officer and 10% owner Eric W. Roberts received an option grant covering 83,358 shares of common stock. The employee stock option has an exercise price of $0.585 per share and expires on April 4, 2036.
According to the vesting terms, beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until the company files a Form S-8 covering shares automatically added under its 2023 Equity Incentive Plan pursuant to an annual evergreen provision.
CalciMedica, Inc. reported that President and COO Michael J. Dunn received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036 and vests in monthly installments over four years, beginning April 1, 2026, after a Form S-8 is filed to cover shares added under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Scientific Officer Kenneth A. Stauderman received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036.
Beginning April 1, 2026, 1/48 of the option vests in equal monthly installments over four years. Vesting will not begin until a Form S-8 is filed covering shares automatically added on January 1, 2026 under the company’s 2023 Equity Incentive Plan evergreen provision.